Iso-osmolar contrast media and adverse renal and cardiac events after percutaneous cardiovascular intervention
Abstract
Aim: To assess the relationship between type of contrast media (CM), iso-osmolar contrast media (IOCM) or low-osmolar contrast media (LOCM), and major adverse renal and cardiovascular events (MARCE). Materials & methods: Coronary or peripheral angioplasty visits were stratified into CM cohorts: IOCM or LOCM. Multivariable regression analysis used hospital fixed effects to assess the relationship between MARCE events and type of CM. Results: Among 333,533 visits (357 hospitals), the incidence of MARCE was 7.41%. After controlling for observable and unobservable time invariant within-hospital characteristics, administration of IOCM versus LOCM was associated with a 0.69% absolute and 9.32% relative risk reduction in MARCE rate. Conclusion: Our study indicates that as compared with LOCM, IOCM may be associated with reduction of MARCE events in coronary or peripheral angioplasty patients.
Supplementary Material
File (suppl_tables_1-3.docx)
- Download
- 22.41 KB
References
Papers of special note have been highlighted as: •• of considerable interest
1.
Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 39(5), 930–936 (2002).
2.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Inter. Suppl. 2, 1–138 (2012).
3.
Harrison JK, Hermiller JB, Vetrovec GW et al. A randomized study of 1276 patients undergoing PCI using iodixanol (Visipaque) vs. iopamidol (Isovue): comparison of in-hospital and 30 day major adverse cardiac events. The results of the VICC trial. Circulation 108(17), S354–S355 (2003).
4.
Nie B, Cheng WJ, Li YF et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc. Interv. 72(7), 958–965 (2008).
5.
Brown JR, Malenka DJ, Devries JT et al. Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry. Catheter Cardiovasc. Interv. 72(3), 347–354 (2008).
6.
Weisbord SD, Chen H, Stone RA et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J. Am. Soc. Nephrol. 17(10), 2871–2877 (2006).
7.
Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. Suppl. 100, S11–S15 (2006).
8.
Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188(1), 171–178 (1993).
9.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am. J. Med. 103(5), 368–375 (1997).
10.
Rudnick MR, Goldfarb S, Wexler L et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 47(1), 254–261 (1995).
11.
Taliercio CP, Vlietstra RE, Ilstrup DM et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J. Am. Coll. Cardiol. 17(2), 384–390 (1991).
12.
Dong M, Jiao Z, Liu T, Guo F, Li G. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. J. Nephrol. 25(3), 290–301 (2012).
13.
Grynne BH, Nossen JO, Bolstad B, Borch KW. Main results of the first comparative clinical studies on Visipaque. Acta Radiol. Suppl. 399, 265–270 (1995).
14.
Jakobsen JA. Renal experience with Visipaque. Eur. Radiol. 6(Suppl. 2), S16–S19 (1996).
15.
McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J. Am. Coll. Cardiol. 48(4), 692–699 (2006).
16.
McCullough PA, Brown JR. Effects of intra-arterial and intravenous iso-osmolar contrast medium (Iodixanol) on the risk of contrast-induced acute kidney injury: a meta-analysis. Cardiorenal Med. 1(4), 220–234 (2011).
•• Meta-analysis of 25 studies found that in high-risk patients with chronic kidney disease, the use of iso-osmolar contrast media was associated with significantly fewer contrast-induced nephropathy events compared with low-osmolar contrast media with intra-arterial administration.
17.
Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int. 76(10), 1089–1097 (2009).
18.
Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin. J. Am. Soc. Nephrol. 9(3), 448–456 (2014).
19.
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 81(5), 442–448 (2012).
20.
Wald R, Quinn RR, Luo J et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302(11), 1179–1185 (2009).
21.
Shaw A. Models of preventable disease: contrast-induced nephropathy and cardiac surgery-associated acute kidney injury. Contrib. Nephrol. 174, 156–162 (2011).
22.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351(13), 1296–1305 (2004).
23.
James MT, Ghali WA, Knudtson ML et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123(4), 409–416 (2011).
24.
Premier Research Services – Premier, Inc. www.premierinc.com.
25.
Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 43(11), 1130–1139 (2005).
26.
3M Health Information Systems. 3M™ APR DRG Software. http://solutions.3m.com/wps/portal/3M/en_US/Health-Information-Systems/HIS/Products-and-Services/Products-List-A-Z/APR-DRG-Software/.
27.
Averill RF, Goldfield N, Hughes JS et al. All Patient Refined Diagnosis Related Groups (APR-DRGs). Methodology overview. Document number GRP–041. Version 20.0 (2003).
28.
Amin AP, Bach RG, Caruso ML, Kennedy KF, Spertus JA. Association of variation in contrast volume with acute kidney injury in patients undergoing percutaneous coronary intervention. JAMA Cardiol. 2(9), 1007–1012 (2017).
29.
Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J. Am. Coll. Cardiol. 44(7), 1393–1399 (2004).
30.
Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur. Heart J. 35(46), 3235–3236 (2014).
31.
Palena LM, Sacco ZD, Brigato C et al. Discomfort assessment in peripheral angiography: randomized clinical trial of Iodixanol 270 versus Ioversol 320 in diabetics with critical limb ischemia. Catheter Cardiovasc. Interv. 84(6), 1019–1025 (2014).
•• Iso-osmolar contrast media may be chosen for high-risk patients due to perceived lower risks of major allergic complications or more tolerable symptoms during injection, particularly with peripheral procedures.
32.
Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 10(5), 326–335 (2007).
Information & Authors
Information
Published In
Copyright
© 2017 Kate Dawson.
History
Received: 12 July 2017
Accepted: 23 October 2017
Published online: 9 November 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Iso-osmolar contrast media and adverse renal and cardiac events after percutaneous cardiovascular intervention. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0052
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Zhaoping Liu, Jian An, Aijie Hou, Yanqin Ren, Lei Qin, Xiaojie Chen, Guozhen Hao, Xi Su, Ping Yang, Guidong Shen, Shenghuang Wang, In-ho Chae, Yong Huo, The Association of Iodixanol With Renal and Cardiovascular Safety in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study, Journal of Cardiovascular Intervention, 10.54912/jci.2025.0014, 5, 1, (38), (2026).
- Rohan Dod, Harika Yadav, Ion S. Jovin, Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2025.2597772, 23, 12, (867-881), (2025).
- Andrea VACIRCA, Gianluca FAGGIOLI, Antonino DI LEO, Sara FRONTERRÈ, Rodolfo PINI, Enrico GALLITTO, Chiara MASCOLI, Stefania CAPUTO, Mauro GARGIULO, How much volume of iodinated contrast medium leads to acute kidney injury in endovascular aortic repair?, International Angiology, 10.23736/S0392-9590.25.05286-1, 44, 1, (2025).
- Pan Li, Boxuan Xu, Xinxin Zhang, Delei Fang, Junxia Zhang, Design and development of a personalized virtual reality-based training system for vascular intervention surgery, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2024.108142, 249, (108142), (2024).
- Xiaozeng Wang, Dengfeng Ma, Tianchang Li, Bao Li, Xi Su, Yanqing Wu, Zhimin Du, Zheng Ji, Ping Yang, Baisong Yang, Xuebin Cao, Junxia Li, Fengxia Hou, Ziping Cheng, Banglong Xu, Yaling Han, Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study, Cardiology Discovery, 10.1097/CD9.0000000000000065, 3, 2, (95-101), (2023).
- Judit Karacsonyi, J. Roberto Martinez-Parachini, Emmanouil S. Brilakis, Acute Kidney Injury Following Percutaneous Coronary Intervention, The American Journal of Cardiology, 10.1016/j.amjcard.2023.08.057, 206, (375-377), (2023).
- Ya Li, Liding Zhao, Tian Xu, Qingbo Lv, Jialin He, Yao Wang, Guosheng Fu, Wenbin Zhang, Association Between Contrast Volume-to-Creatinine Clearance Ratio and the Risk of Perioperative Myocardial Infarction After Elective Percutaneous Coronary Intervention, International Heart Journal, 10.1536/ihj.21-678, 63, 5, (798-805), (2022).
- Ion S. Jovin, Theodore J. Warsavage, Mary E. Plomondon, Gary K. Grunwald, Stephen W. Waldo, Sunil V. Rao, Emmanouil S. Brilakis, Lorenzo Azzalini, Iso‐osmolar versus low‐osmolar contrast media and outcomes after percutaneous coronary intervention: Insights from the VA CART Program, Catheterization and Cardiovascular Interventions, 10.1002/ccd.30218, 100, 1, (85-93), (2022).
- F.G. Moser, T.M. Todoran, M. Ryan, E. Baker, C. Gunnarsson, J.A. Kellum, Hemorrhagic Transformation Rates following Contrast Media Administration in Patients Hospitalized with Ischemic Stroke, American Journal of Neuroradiology, 10.3174/ajnr.A7412, 43, 3, (381-387), (2022).
- Anand Prasad, Amit P. Amin, Michael P. Ryan, Candace Gunnarsson, Emmanouil S. Brilakis, Use of iso‐osmolar contrast media during endovascular revascularization is associated with a lower incidence of major adverse renal, cardiac, or limb events , Catheterization and Cardiovascular Interventions, 10.1002/ccd.30006, 99, 4, (1335-1342), (2021).